General Partner Inc. Makes New Investment in Hologic, Inc. (NASDAQ:HOLX)

General Partner Inc. bought a new stake in Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, Holdings Channel reports. The fund bought 365 shares of the medical equipment provider’s stock, valued at approximately $26,000.

Other hedge funds also recently modified their holdings of the company. Andra AP fonden boosted its stake in Hologic by 224.5% in the second quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider’s stock valued at $7,083,000 after acquiring an additional 66,000 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Hologic by 17.9% in the 3rd quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock valued at $312,000 after purchasing an additional 582 shares during the period. Janus Henderson Group PLC boosted its position in shares of Hologic by 2.9% in the 3rd quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock worth $2,344,000 after purchasing an additional 800 shares during the last quarter. Quest Partners LLC grew its stake in shares of Hologic by 56.1% during the second quarter. Quest Partners LLC now owns 41,492 shares of the medical equipment provider’s stock worth $3,081,000 after purchasing an additional 14,914 shares during the period. Finally, Versor Investments LP bought a new stake in Hologic in the third quarter valued at about $1,677,000. Institutional investors own 94.73% of the company’s stock.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.75% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have issued reports on HOLX shares. Raymond James raised their target price on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Wolfe Research began coverage on shares of Hologic in a research note on Friday, December 13th. They set a “peer perform” rating on the stock. JPMorgan Chase & Co. upped their target price on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Leerink Partners reduced their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Finally, Mizuho lowered their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Six investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $89.50.

Hologic Stock Up 0.5 %

Shares of Hologic stock traded up $0.35 during trading on Friday, reaching $72.09. The stock had a trading volume of 156,468 shares, compared to its average volume of 632,277. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $16.36 billion, a price-to-earnings ratio of 21.65, a P/E/G ratio of 2.32 and a beta of 0.96. The stock has a fifty day moving average price of $76.87 and a two-hundred day moving average price of $78.43. Hologic, Inc. has a 52 week low of $70.36 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same quarter in the prior year, the firm posted $0.89 EPS. The business’s revenue was up 4.5% on a year-over-year basis. Sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.